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The success of acute lymphoblastic leukemia therapy is a consequence of numerous 
studies that have being conducted since 1950. At first, treatment was introduced in a 
trial and error method, but afterwards it was based on scientific knowledge drained from 
observational and laboratory research. If, on one hand, a group of drugs was established 
as the main therapeutic option since impressive results were observed after their use, 
on the other, patient and leukemic cell features were also detected as important for 
treatment outcome(1). In fact, conventional risk criteria presented at diagnosis, such as 
age, elevated white blood cell count, adverse immunophenotypic pattern and cytogenetic 
or molecular aberrations provide the basis for upfront risk stratification. However, patient 
performance status, concomitant diseases, treatment compliance, host pharmacodynamics 
and pharmacogenetics are also relevant. In addition, proprieties of the leukemia cell, such 
as proliferative capacity, susceptibility to drugs or escape mechanism as well as intensity 
of drugs to eradicate the disease compose the group of features in which treatment 
outcomes depend. Notwithstanding this, relapses were still a problem and the main cause 
of reduction of survival. Indeed, the criteria used to define remission after induction 
chemotherapy (less than 5% of blasts in the marrow with hematological recovery) did 
not mean that leukemia cells were totally eradicated, but that their level was beyond the 
sensitivity limits of classic morphology methods. In most of these situations, malignant 
cells still remained representing minimal residual disease (MRD)(2). The source of relapse 
was persistent MRD. In order to detect the level of MRD, diagnostic improvements were 
achieved by evaluations either by molecular genetic methods or by ﬂow cytometry, which 
has been shown to be predictive for outcome in a number of studies on children and adults. 
Furthermore, MRD monitoring during the first year of intensive chemotherapy led to an 
MRD-based risk stratification. Thereafter, protocols have been designed considering MDR 
as an important aspect to allow a tailored treatment in order to achieve a longer survival 
and it is now established that the level of MDR represents a powerful prognostic factor 
as well. In addition, when MRD monitoring shows increasing levels one can anticipate 
impending relapse(3). Consequently, a prerequisite for the application of MRD to tailor 
treatment is an adequate, sensitive and standardized method. Most of these methods are 
expensive, quite complex and require expertise. A low cost, reliable and easy to perform 
methodology is desired. This was precisely what Assumpção et al. are presenting in their 
paper published in this issue of Revista Brasileira de Hematologia e hemoterapia(4). These 
authors tried to detect markers in MRD monitoring based on conventional polymerase 
chain reaction (PCR) for immunoglobulin (Ig) and T-cell receptor (TCR) rearrangements, 
and Sil-Tal1 deletion in patients with acute lymphoblastic leukemia (ALL) treated in 
three hospitals in Minas Gerais, Brazil. The methodology proposed has a low sensitivity 
to detect small amounts of residual cells nevertheless it allowed the discrimination of 
high-risk patients. Certainly, there is a long way to go before these methods may be 
considered a good option, and studies comparing them with gold-standard techniques are 
being performed. Therefore the feeling that the best is yet to come can be detected from 
ongoing research.
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